Niagen Bioscience (NAGE) Competitors $9.98 +0.21 (+2.15%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAGE vs. KYMR, AMRX, XENE, VKTX, MOR, RARE, BHC, ARWR, HCM, and CRNXShould you be buying Niagen Bioscience stock or one of its competitors? The main competitors of Niagen Bioscience include Kymera Therapeutics (KYMR), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), MorphoSys (MOR), Ultragenyx Pharmaceutical (RARE), Bausch Health Cos (BHC), Arrowhead Pharmaceuticals (ARWR), HUTCHMED (HCM), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Niagen Bioscience vs. Its Competitors Kymera Therapeutics Amneal Pharmaceuticals Xenon Pharmaceuticals Viking Therapeutics MorphoSys Ultragenyx Pharmaceutical Bausch Health Cos Arrowhead Pharmaceuticals HUTCHMED Crinetics Pharmaceuticals Niagen Bioscience (NASDAQ:NAGE) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Is NAGE or KYMR more profitable? Niagen Bioscience has a net margin of 15.24% compared to Kymera Therapeutics' net margin of -616.03%. Niagen Bioscience's return on equity of 23.12% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience15.24% 23.12% 15.53% Kymera Therapeutics -616.03%-31.60%-27.12% Which has more risk and volatility, NAGE or KYMR? Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Do institutionals & insiders believe in NAGE or KYMR? 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Niagen Bioscience shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, NAGE or KYMR? Niagen Bioscience has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$116.30M6.84$8.55M$0.2147.52Kymera Therapeutics$47.07M66.99-$223.86M-$3.47-12.71 Do analysts recommend NAGE or KYMR? Niagen Bioscience currently has a consensus price target of $13.42, indicating a potential upside of 34.47%. Kymera Therapeutics has a consensus price target of $59.11, indicating a potential upside of 34.04%. Given Niagen Bioscience's higher probable upside, equities analysts plainly believe Niagen Bioscience is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10 Does the media prefer NAGE or KYMR? In the previous week, Kymera Therapeutics had 8 more articles in the media than Niagen Bioscience. MarketBeat recorded 15 mentions for Kymera Therapeutics and 7 mentions for Niagen Bioscience. Kymera Therapeutics' average media sentiment score of 0.68 beat Niagen Bioscience's score of 0.11 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNiagen Bioscience beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Niagen Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for NAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAGE vs. The Competition Export to ExcelMetricNiagen BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$795.94M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio47.5321.1431.1525.97Price / Sales6.84399.83475.57123.18Price / Cash162.8143.0937.1558.38Price / Book12.488.079.116.39Net Income$8.55M-$54.72M$3.26B$265.66M7 Day Performance-0.40%2.62%2.11%1.98%1 Month Performance5.61%7.63%5.12%1.33%1 Year PerformanceN/A13.11%31.25%21.15% Niagen Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAGENiagen Bioscience1.3517 of 5 stars$9.98+2.1%$13.42+34.5%N/A$795.94M$116.30M47.53120KYMRKymera Therapeutics3.0894 of 5 stars$42.35-0.5%$59.11+39.6%-12.3%$3.03B$44.71M-12.20170AMRXAmneal Pharmaceuticals3.3522 of 5 stars$9.41+0.9%$11.60+23.3%+17.1%$2.96B$2.79B941.948,100News CoveragePositive NewsInsider TradeXENEXenon Pharmaceuticals2.0966 of 5 stars$37.64+0.7%$53.20+41.3%-2.5%$2.90B$9.43M-10.60210Options VolumeVKTXViking Therapeutics4.0243 of 5 stars$25.69+5.5%$86.92+238.4%-60.4%$2.89BN/A-16.7920Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsRAREUltragenyx Pharmaceutical4.7233 of 5 stars$29.36+0.8%$81.50+177.6%-48.3%$2.83B$560.23M-5.311,294News CoverageBHCBausch Health Cos4.3462 of 5 stars$7.60-2.5%$9.00+18.5%+28.7%$2.81B$9.63B29.2120,700Analyst RevisionARWRArrowhead Pharmaceuticals3.7734 of 5 stars$20.20+1.7%$43.14+113.6%-17.8%$2.79B$3.55M-15.78400HCMHUTCHMED2.736 of 5 stars$15.88-2.0%$28.00+76.3%-10.2%$2.77B$630.20M0.001,811CRNXCrinetics Pharmaceuticals3.701 of 5 stars$29.09-1.2%$68.86+136.7%-45.5%$2.74B$1.39M-7.08210News CoverageInsider Trade Related Companies and Tools Related Companies KYMR Competitors AMRX Competitors XENE Competitors VKTX Competitors MOR Competitors RARE Competitors BHC Competitors ARWR Competitors HCM Competitors CRNX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAGE) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access